Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

scientific article published on 22 January 2016

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/ANNONC/MDW008
P932PMC publication ID4803455
P698PubMed publication ID26802155

P50authorGiuseppe GiacconeQ37829946
Karen L. ReckampQ46041139
Sean KhozinQ48504033
Eva SzaboQ69483163
Everett E VokesQ73567428
Jane B TrepelQ111692206
P2093author name stringR Salgia
M J Lee
M Raffeld
C A Carter
A Thomas
S Lee
S M Steinberg
L Xi
L A Doyle
D Gandara
A Rajan
Y Tomita
S Koehler
C Keen
B Gitlitz
U Guha
C Brzezniak
P2860cites workKRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibQ21563446
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumorsQ24294914
Somatic mutations affect key pathways in lung adenocarcinomaQ24648102
Cancer statistics, 2014Q27861018
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Q28131668
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesQ28289431
Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocationQ28609161
How MAP kinases are regulatedQ28609360
Erlotinib in previously treated non-small-cell lung cancerQ29547546
BRAF mutation predicts sensitivity to MEK inhibitionQ29614281
Immunogenic cell death in cancer therapyQ29620118
Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell linesQ34129528
RET, ROS1 and ALK fusions in lung cancerQ34253845
MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitroQ34615021
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trialQ35168763
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerQ37274280
New targets in advanced NSCLC: EML4-ALK.Q37862973
The secret ally: immunostimulation by anticancer drugsQ37981038
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerQ38432430
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptorsQ39355055
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitorQ40164535
A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic RegimensQ42673662
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancerQ43152544
Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutationsQ43179196
Imbalance in the Th17/Treg and cytokine environment in peripheral blood of patients with adenocarcinoma and squamous cell carcinomaQ45152931
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialQ46542092
K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.Q52914148
Chemotherapy for non-small cell lung cancerQ71791935
P433issue4
P921main subjecterlotinibQ418369
P304page(s)693-699
P577publication date2016-01-22
P1433published inAnnals of OncologyQ326122
P1476titleSelumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer
P478volume27

Reverse relations

cites work (P2860)
Q55339149A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.
Q42363767A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
Q55259943A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types.
Q39220897Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.
Q50345931Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes
Q47145152Correlation between MEK signature and Ras gene alteration in advanced gastric cancer
Q42700668Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials
Q39538184Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials
Q39145987Functional exploration of colorectal cancer genomes using Drosophila
Q48877738Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
Q38899873Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer
Q90326601Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials
Q49787333Implications of KRAS mutations in acquired resistance to treatment in NSCLC.
Q37743107Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
Q37709450KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies
Q49887897KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Q42332672Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design
Q93018169MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells
Q47318847MEK inhibitors under development for treatment of non-small-cell lung cancer
Q60915896Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
Q96302844RAS-targeted therapies: is the undruggable drugged?
Q38792704Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial
Q38663069Selumetinib for the treatment of non-small cell lung cancer
Q38836927Selumetinib in the treatment of non-small-cell lung cancer
Q47671139Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.
Q64374979The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
Q37477372The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinosta
Q39045958The role of the immune system in neurofibromatosis type 1-associated nervous system tumors

Search more.